Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27960653 | 1.00 | CES2 (0.50) | CES2CES1LMNAKDM4EPTPN1 | |
| Methyl Alcohol SCHEMBL27960708 | 0.98 | CES2 (0.49) | CES2CES1LMNAKDM4EPTPN1 | |
| SCHEMBL8576290 | 0.87 | MEN1 (0.43) | CES2CES1LMNAKDM4EPTPN1 | |
| SCHEMBL17290348 | 0.86 | CES2 (0.47) | CES2CES1LMNAKDM4EPTPN1 | |
| SCHEMBL26597084 | 0.83 | KDM4E (0.46) | CES2CES1LMNAKDM4EPTPN1 | |
| SCHEMBL1878466 | 0.80 | SLC6A2 (0.48) | KDM4EERCC5FEN1GAAALDH1A1 | |
| SCHEMBL19333968 | 0.80 | CES2 (0.51) | CES2CES1LMNAKDM4EPTPN1 | |
| SCHEMBL10798460 | 0.80 | CES2 (0.51) | CES2CES1LMNAKDM4EPTPN1 | |
| SCHEMBL2291303 | 0.79 | CES2 (0.53) | CES2CES1MEN1KMT2A | |
| SCHEMBL2292145 | 0.79 | ALDH1A1 (0.52) | CES2CES1ERCC5FEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108059609-A | The new preparation process of Ezetimibe | 武汉启瑞药业有限公司 | 2018-05-22 | — | — | CN | claimed |
| CN-108059608-A | A kind of preparation method of Ezetimibe | 武汉启瑞药业有限公司 | 2018-05-22 | — | — | CN | claimed |
| CN-104744390-A | Preparation method of ezetimibe internmediate ketone | UNIV NANJING NORMAL | 2015-07-01 | — | — | CN | claimed |
| CN-102605034-B | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2014-05-14 | — | — | CN | claimed |
| CN-102605034-A | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2012-07-25 | — | — | CN | claimed |
| WO-2023164877-A1 | FULLERENE DERIVATIVE AND PEROVSKITE SOLAR CELL | 宁德时代新能源科技股份有限公司 | 2023-09-07 | — | — | WO | disclosed |
| CN-108059609-A | The new preparation process of Ezetimibe | 武汉启瑞药业有限公司 | 2018-05-22 | — | — | CN | disclosed |
| CN-108059608-A | A kind of preparation method of Ezetimibe | 武汉启瑞药业有限公司 | 2018-05-22 | — | — | CN | disclosed |
| CN-204918429-U | Production is to mechanical device of fluorine benzoyl butyric acid | XINYI WANYU INDUSTRY AND TRADE CO LTD | 2015-12-30 | — | — | CN | disclosed |
| CN-104744390-A | Preparation method of ezetimibe internmediate ketone | UNIV NANJING NORMAL | 2015-07-01 | — | — | CN | disclosed |
| CN-102605034-B | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2014-05-14 | — | — | CN | disclosed |
| WO-2012173504-A2 | METHOD FOR SYNTHESIS OF THE SUBSTITUTED AZETIDINONES AND INTERMEDIATES FOR THEIR SYNTHESIS | Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) | 2012-12-20 | — | — | WO | disclosed |
| WO-2007144780-A2 | PROCESSES FOR PREPARING EZETIMIBE AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION THEREOF | MEDICHEM S.A. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007119106-A2 | PROCESSES FOR PREPARING INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF EZETIMIBE | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007108007-A1 | A PROCESS FOR THE PREPARATION OF EZETIMIBE VIA A NOVEL INTERMEDIATE | UNICHEM LABORATORIES LIMITED (IN) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| EP-0858996-B1 | NERVE CELL PROTECTIVE AGENTS | MOCHIDA PHARM CO LTD (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6040331-A | Nerve cell protective agents | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-21 | — | — | US | disclosed |
| EP-0858996-A1 | NERVE CELL PROTECTIVE AGENTS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | CES2 2776/4885CES1 1734/4885LMNA 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.